Clinical Trial Update: In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients

View source ↗

Summary

This completed trial update reports in vitro evidence that concizumab (an anti-TFPI antibody) corrected thrombin generation in samples from patients with severe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Concizumab (concizumab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Hemophilia | Status: COMPLETED